Latest Ratios: P/E Ratio -2.6x · EV/EBITDA N/A · ROE -54.1%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $116M | $213M | $216M | $160M | $265M | $514M | $210M | $407M | $537M | $82M | $114M |
| Enterprise Value | $15M | $121M | $78M | $51M | $187M | $370M | $159M | $296M | $425M | $33M | $57M |
| P/E Ratio → | -2.60 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 5.68 | 13.93 | 11.45 | 24.62 | 73.75 | 385.09 | 204.33 | 210.39 | 108.75 | — | 50.13 |
| P/B Ratio | 1.82 | 3.67 | 2.36 | 3.51 | 3.72 | 3.99 | 3.04 | 3.86 | 5.07 | 1.74 | 2.04 |
| P/FCF | — | — | — | 7.95 | — | — | — | — | — | — | — |
| P/OCF | — | — | — | 7.44 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.90 | 4.11 | 7.80 | 52.13 | 276.78 | 154.91 | 153.25 | 85.95 | — | 24.89 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | 2.52 | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.0% | 83.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -5943.6% | 80.1% | 165.5% | 43.8% |
| Operating Margin | -275.9% | -275.9% | -161.2% | -489.1% | -1813.0% | -4285.4% | -4117.4% | -2971.8% | -734.5% | 2648.7% | -1734.1% |
| Net Profit Margin | -265.2% | -265.2% | -146.9% | -431.7% | -1792.5% | -4549.8% | -4525.3% | -2935.6% | -746.7% | 2854.0% | -1713.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -54.1% | -54.1% | -40.4% | -48.1% | -64.4% | -61.4% | -53.4% | -53.7% | -48.2% | -84.5% | -53.6% |
| ROA | -26.5% | -26.5% | -17.0% | -16.8% | -30.6% | -33.8% | -36.8% | -44.0% | -38.9% | -65.7% | -46.2% |
| ROIC | — | — | — | — | — | -3430.3% | -480.7% | — | — | — | — |
| ROCE | -37.0% | -37.0% | -24.6% | -23.2% | -35.5% | -36.3% | -37.2% | -48.6% | -42.6% | -70.1% | -50.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.28 | 0.18 | 0.48 | 0.33 | 0.53 | 0.61 | 0.14 | 0.08 | 0.18 | 0.09 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.59 | -1.51 | -2.40 | -1.09 | -1.12 | -0.73 | -1.05 | -1.06 | -1.04 | -1.03 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | -5.43 | — | — | — | — | — | — | — |
| Interest Coverage | -45.75 | -45.75 | -24.96 | -22.12 | -11.50 | -16.82 | -24.90 | -159.14 | -44.78 | -67.95 | -69.16 |
Net cash position: cash ($109M) exceeds total debt ($16M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.09 | 3.09 | 3.95 | 3.54 | 7.36 | 6.94 | 7.77 | 10.43 | 13.28 | 5.95 | 9.24 |
| Quick Ratio | 3.09 | 3.09 | 3.95 | 3.54 | 7.36 | 6.94 | 7.77 | 10.43 | 13.28 | 5.95 | 9.24 |
| Cash Ratio | 2.85 | 2.85 | 3.84 | 3.48 | 4.52 | 6.80 | 7.36 | 10.18 | 12.94 | 5.66 | 8.82 |
| Asset Turnover | — | 0.12 | 0.11 | 0.04 | 0.02 | 0.01 | 0.01 | 0.01 | 0.04 | -0.02 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 142.70 | 40.52 | 78.49 | 6203.69 | 255.89 | 347.21 | 252.23 | 180.88 | -134.44 | 264.02 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | 12.6% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $105M | $82M | $81M | $72M | $64M | $50M | $41M | $34M | $25M | $23M |
Includes 30+ ratios · 13 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRQR stock.
ProQR Therapeutics N.V.'s current P/E ratio is -2.6x. This places it at the 50th percentile of its historical range.
ProQR Therapeutics N.V.'s return on equity (ROE) is -54.1%. The historical average is -50.4%.
Based on historical data, ProQR Therapeutics N.V. is trading at a P/E of -2.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
ProQR Therapeutics N.V. has 83.0% gross margin and -275.9% operating margin.
Key Metrics
Top Statement Risk
Shrinking cash runway versus persistent burn
Premium Book Multiple Against Losses
Based on reported figures, PRQR trades at 8.33 times sales and 2.19 times book with a trailing P/E of -3.18, a pricing structure that rests on pipeline value rather than current earnings power.
With no positive earnings and no free cash flow yield, the valuation cannot be anchored to conventional earnings or cash multiples, so the 2.19 price-to-book figure is the most usable reference point. Relative to peers such as NTLA at 1.83 and BEAM at 2.11, PRQR carries a similar or modestly higher book multiple despite a comparable loss profile. Investors should monitor whether the market continues to attribute value to the clinical pipeline as cash reserves decline, since the multiple appears to embed expectations that the reported figures do not yet demonstrate.
Operating Losses Dominate Earnings Power
As reported in the income statement, PRQR's operating margin was -100.7% in 2026Q2 and has remained deeply negative across most quarters, with net margin of -99.6% in the latest period.
Gross margin has stayed near 100% in most quarters, which reflects the collaboration revenue structure rather than a product cost base, so gross margin offers little information about true earning power. The more informative measure is operating margin, which has been consistently negative and largely driven by R&D spending that exceeds revenue in most periods. Any single quarter with elevated revenue, such as the latest, should be viewed with caution until it recurs.
Low Debt Despite Shrinking Equity Base
Based on reported figures, PRQR's debt-to-equity ratio fell to 0.17 in 2026Q2 from 0.63 in 2024Q3, though this decline reflects a shrinking equity denominator more than deliberate deleveraging.
Interest coverage is not meaningful given negative operating income, and debt servicing capacity depends on the cash balance rather than earnings. The decline in the debt ratio coincides with equity erosion from accumulated losses, so the lower ratio may overstate balance sheet strength. Refinancing or covenant risk cannot be assessed from the supplied data beyond noting the absence of interest coverage support.
Liquidity Strong on Paper, Finite in Practice
As reported in financial statements, PRQR's current ratio stood at 3.49 in 2026Q2, supported by a cash-heavy asset base, though this figure does not account for the rate at which cash is being consumed.
The quick ratio equals the current ratio because inventory is negligible, so liquidity depends almost entirely on cash and receivables rather than operating assets. Under a severe stress scenario with sustained operating cash burn, the current cushion would erode over a finite period, and the reported figures do not disclose a funded runway. Investors should monitor quarterly cash depletion against the reported balance to estimate how long the current position can sustain operations without new capital.
Ratio Most Misapplied: Gross Margin
Based on reported figures, PRQR's gross margin of 91.9% to 100.0% for most quarters is often read as a sign of pricing power, yet for a collaboration-revenue biotech it obscures the operating losses that actually define the business.
Gross margin for a collaboration-driven company reflects the absence of cost of goods sold on licensing income rather than product economics, so a high figure can mislead investors into assuming scalable profitability. Operating margin, combined with cash burn relative to reserves, is a more appropriate measure of the company's financial position. Analysts should instead track operating cash flow against cash balance to gauge the time remaining before additional financing is needed.